670 results match your criteria Surveillance for Recurrent Bladder Cancer


Assessment of quality of life, information, and supportive care needs in patients with muscle and non-muscle invasive bladder cancer across the illness trajectory.

Support Care Cancer 2019 Feb 14. Epub 2019 Feb 14.

Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, Toronto, Canada.

Background: To date, little research has examined the quality of life and cancer-associated needs of bladder cancer patients. The objective of the current study was to assess the quality of life (QoL), informational needs, and supportive care needs (SCN) in a large sample of muscle invasive (MIBC) and non-muscle invasive (NMIBC) bladder cancer survivors across the treatment trajectory (newly diagnosed and undergoing treatment, post-treatment follow-up, and treatment for advanced/recurrent disease).

Methods: Questionnaires were distributed to a convenience sample of patients registered with Bladder Cancer Canada, the Princess Margaret Cancer Centre, or The Ottawa Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-4649-zDOI Listing
February 2019

BCG Renal Granuloma.

Urology 2019 Feb 7. Epub 2019 Feb 7.

Denver Veterans Affairs Medical Center, Aurora, CO, USA.

A 66-year-old gentlemen with a history of recurrent urothelial carcinoma in situ treated with endoscopic resection and induction BCG developed a new renal mass on surveillance computerized tomography (CT) and was referred to our institution for surgery. Biopsy was performed and pathology showed BCG granuloma. The patient was clinically asymptomatic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2019.01.026DOI Listing
February 2019

MicroRNA dysregulation and non-muscle invasive bladder cancer prognosis.

Cancer Epidemiol Biomarkers Prev 2019 Jan 30. Epub 2019 Jan 30.

Dartmouth-Hitchcock Medical Center.

Background: The high rate of non-muscle invasive bladder cancer recurrence is a major challenge in patient management. microRNAs (miRNAs) functionally regulate tumor cell proliferation and invasion, and have strong potential as biomarkers, since they are robust to degradation. The objective of this project was to identify reproducible prognostic miRNAs in resected non-muscle invasive bladder tumor tissue that are predictive of the recurrent tumor phenotype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-18-0884DOI Listing
January 2019
1 Read

Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.

BJU Int 2019 Jan 17. Epub 2019 Jan 17.

Department of Urology, Medical University of Vienna, Vienna, Austria.

Objectives: To investigate prospectively the clinical utility and influence on decision-making of Bladder EpiCheck™, a non-invasive urine test, in the surveillance of non-muscle-invasive bladder cancer (NMIBC).

Materials And Methods: Urine samples from 440 patients undergoing surveillance for NMIBC were prospectively collected at five centres and evaluated using the Bladder EpiCheck test (NCT02647112). A multivariable nomogram and decision-curve analysis (DCA) were used to evaluate the impact of Bladder EpiCheck on decision-making when used in routine clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14673DOI Listing
January 2019
1 Read

Recurrent activating mutations of PPARγ associated with luminal bladder tumors.

Nat Commun 2019 01 16;10(1):253. Epub 2019 Jan 16.

Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, 75005, Paris, France.

The upregulation of PPARγ/RXRα transcriptional activity has emerged as a key event in luminal bladder tumors. It renders tumor cell growth PPARγ-dependent and modulates the tumor microenvironment to favor escape from immuno-surveillance. The activation of the pathway has been linked to PPARG gains/amplifications resulting in PPARγ overexpression and to recurrent activating point mutations of RXRα. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-08157-y
Publisher Site
http://dx.doi.org/10.1038/s41467-018-08157-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335423PMC
January 2019
8 Reads

Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer.

Proteomics Clin Appl 2019 Jan 11:e1800148. Epub 2019 Jan 11.

Proteomics Laboratory, Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, 11527, Greece.

Purpose: To evaluate the diagnostic and prognostic performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) in detecting urinary bladder cancer (UBC).

Methods: The Integrated Study on Bladder Cancer (n = 571; mean age:69.4 ± 12. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/prca.201800148
Publisher Site
http://dx.doi.org/10.1002/prca.201800148DOI Listing
January 2019
2 Reads

Recurrent ovarian mixed germ cell tumor with unusual malignant transformation: a case report.

J Ovarian Res 2019 Jan 10;12(1). Epub 2019 Jan 10.

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital and National Yang-Ming University, 201, Section 2, Shih-Pai Road, Taipei, 112, Taiwan, Republic of China.

Background: The value of this report is the identification of late recurrence with an extremely unusual combination of malignant transformation. In particular, the retroconversion of immature to mature teratoma as well as a somatic-type malignant transformation were both observed postchemotherapeutically in our case.

Case Presentation: We report the case of a 20-year-old girl who completed fertility-sparing surgery and chemotherapy under the diagnosis of ovarian mixed germ cell tumor (immature teratoma and yolk sac tumor) and experienced subsequent recurrence 4 years after a second debulking surgery with a somatic type malignant transformation (teratoma with melanoma and leiomyosarcoma). Read More

View Article

Download full-text PDF

Source
https://ovarianresearch.biomedcentral.com/articles/10.1186/s
Publisher Site
http://dx.doi.org/10.1186/s13048-018-0476-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327407PMC
January 2019
5 Reads

Preneoplastic Lesion in a Pancreas Allograft: Dilemma for the Pancreas Transplant Surgeon.

Transplant Proc 2018 Dec 30;50(10):3694-3697. Epub 2018 Jun 30.

Division of Transplantation, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN.

Although the relationship between immunosuppression and cancer risk is well-documented, the association between immunosuppression and the development of preneoplastic lesions (PNL) is less clear. PNLs pose a unique clinical conundrum in the transplanted pancreas because their prevalence in the general population is not infrequent. We present the case of a 58-year-old man with a history of diabetes mellitus type 1 who underwent successful pancreas transplantation with bladder drainage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2018.06.047DOI Listing
December 2018
1 Read

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.

Eur Urol 2018 Dec 12. Epub 2018 Dec 12.

Radboudumc, Nijmegen, The Netherlands.

Background: A fast, noninvasive test with high sensitivity (SN) and a negative predictive value (NPV), which is able to detect recurrences in bladder cancer (BC) patients, is needed. A newly developed urine assay, Xpert Bladder Cancer Monitor (Xpert), measures five mRNA targets (ABL1, CRH, IGF2, UPK1B, and ANXA10) that are frequently overexpressed in BC.

Objective: To validate Xpert characteristics in patients previously diagnosed with non-muscle-invasive BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.11.055DOI Listing
December 2018

Micronuclei frequency in urothelial cells of bladder cancer patients, as a biomarker of prognosis.

Environ Mol Mutagen 2019 03 4;60(2):168-173. Epub 2018 Oct 4.

Grup de Mutagènesi, Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, Campus de Bellaterra, 08193, Barcelona, Spain.

It has been suggested that the frequency of micronuclei (MN) in defoliated urothelial cells could be used as a biomarker for both the potential risk of bladder cancer (BC) and its progression. To prove this we have carried out a large study evaluating the MN frequency in a group of 383 hospital patients submitted to cystoscopy. From them, 77 were negative in their first cystoscopy, and were considered as a reference group; 79 were positive and were classified as patients with tumor; and 227 with previous bladder cancer submitted to follow-up monitoring were negative and classified as BC patients without tumor. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/em.22252
Publisher Site
http://dx.doi.org/10.1002/em.22252DOI Listing
March 2019
9 Reads

The conundrum of recurrent low-grade tumours: to treat or to observe?

Curr Opin Urol 2018 Nov;28(6):557-562

Department of urology, University of Rochester School of Medicine, Rochester, New York, USA.

Purpose Of Review: To describe the importance of risk stratification and the role of more conservative management like office fulguration, office laser ablation and active surveillance in recurrent low-grade Ta tumours.

Recent Findings: Updated models have been designed for risk stratification of intermediate-risk tumours. Conservative forms of management like office fulguration or laser ablation and even active surveillance seem well tolerated; however, randomized, controlled trials are lacking. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00042307-900000000-9916
Publisher Site
http://dx.doi.org/10.1097/MOU.0000000000000550DOI Listing
November 2018
2 Reads

Case 258: Granulomatous Prostatitis.

Radiology 2018 Oct;289(1):267-271

From the Departments of Radiology (A.D.d.L., D.N.C., I.P.), Urology (I.P.), and Pathology (F.F.), and the Advanced Imaging Research Center (D.N.C., I.P.), University of Texas Southwestern Medical Center, 2201 Inwood Rd, 2nd Floor, Suite 202, Dallas, TX 75390-9085.

History A 68-year-old man with a remote history of a previously resected high-grade urothelial carcinoma in the renal pelvis was being observed and was undergoing urologic treatment for recurrent low-grade urothelial carcinoma of the bladder. During his most recent evaluation, he reported no specific symptoms and denied experiencing hematuria, dysuria, or abdominal pain. At routine surveillance MRI of the abdomen and pelvis (images not shown), a lesion was noted in the peripheral zone of the prostate gland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2018161272DOI Listing
October 2018
11 Reads

Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.

Curr Urol Rep 2018 Sep 13;19(11):94. Epub 2018 Sep 13.

Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Purpose Of Review: There are an estimated 33 million men and women with overactive bladder (OAB) in the USA. Despite the prevalence of OAB, it remains a frequently misdiagnosed condition. OAB has shared symptomatology with other common urologic conditions, namely recurrent urinary tract infections (UTIs). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11934-018-0839-3
Publisher Site
http://dx.doi.org/10.1007/s11934-018-0839-3DOI Listing
September 2018
37 Reads

Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer.

Cell Physiol Biochem 2018 16;48(6):2364-2373. Epub 2018 Aug 16.

Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background/aims: This study aimed to validate the value of urothelial stem cell (USC) markers ΔNp63, integrin β4, CD47, and CD44v6 in predicting the prognosis of non-muscle invasive bladder cancer (NMIBC) located in different anatomic regions of bladder.

Methods: The study reviewed the clinicopathologic data of 169 patients with NMIBC. Using real-time PCR and immunohistochemistry, the expression of ΔNp63, integrin β4, CD47, and CD44v6 in archived specimens of patients with NMIBC were validated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492652DOI Listing
September 2018
5 Reads
2.880 Impact Factor

Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study.

Bladder Cancer 2018 Jul 30;4(3):303-310. Epub 2018 Jul 30.

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Objectives: To investigate the role of fluid intake from beverages before and after a diagnosis of bladder cancer in relation to the risk of developing bladder cancer recurrence.

Study Design: Prospective cohort study.

Methods: 716 patients with non-muscle invasive bladder cancer (NMIBC), who received transurethral resection of a primary bladder tumour (TURBT) and completed self-administrated questionnaires on usual fluid intake from beverages at time of diagnosis (over the year before diagnosis) and during follow-up (over the year after diagnosis), were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-180172DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087451PMC
July 2018
3 Reads

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

World J Urol 2019 Jan 14;37(1):51-60. Epub 2018 Aug 14.

Division of Urology, McGill University Health Center-Glen Site, 1001 Decarie Blvd, Montreal, QC, H3A 3J1, Canada.

Purpose: To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the management of non-muscle invasive bladder cancer (NMIBC).

Methods: A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-018-2438-9DOI Listing
January 2019
19 Reads

An unusual diverticulum adjacent to two large colonic polyps; a case report.

BMC Gastroenterol 2018 Jun 14;18(1):83. Epub 2018 Jun 14.

Department of Gastroenterology, Sheffield Teaching Hospitals, Northern General Hospital, Herries Road, Sheffield, S5 7AU, England.

Background: Adenocarcinomas can arise in a variety of circumstances in which intestinal segments have been used for urinary diversions. Whereas ureterosigmoidostomy is the oldest and simplest form of continent urinary diversion it also seems to be the most dangerous in this regard. Herein we present a case of colonic neoplasia complicating a non-functioning ureterosigmoidostomy after 55 years; the longest latent period documented to date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-018-0816-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001174PMC
June 2018
6 Reads

Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study.

Cancer Causes Control 2018 Jun 17;29(6):573-579. Epub 2018 Apr 17.

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Introduction: There is some evidence that greater consumption of fruit and vegetables decreases the risk of bladder cancer. The role of fruit and vegetables in bladder cancer recurrence is still unknown.

Objective: The role of total fruit and vegetable intake in relation to the risk of developing bladder cancer recurrence in a prospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-018-1029-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938309PMC
June 2018
7 Reads

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.

Cell Rep 2018 Apr;23(1):194-212.e6

Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, MD 20892, USA. Electronic address:

This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with smoking and/or human papillomavirus (HPV). SCCs harbor 3q, 5p, and other recurrent chromosomal copy-number alterations (CNAs), DNA mutations, and/or aberrant methylation of genes and microRNAs, which are correlated with the expression of multi-gene programs linked to squamous cell stemness, epithelial-to-mesenchymal differentiation, growth, genomic integrity, oxidative damage, death, and inflammation. Low-CNA SCCs tended to be HPV(+) and display hypermethylation with repression of TET1 demethylase and FANCF, previously linked to predisposition to SCC, or harbor mutations affecting CASP8, RAS-MAPK pathways, chromatin modifiers, and immunoregulatory molecules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.03.063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002769PMC
April 2018
15 Reads

Does switching the bacillus Calmette-Guérin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?

Urol Oncol 2018 Jun 9;36(6):306.e1-306.e8. Epub 2018 Mar 9.

Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.

Purpose: It is still unknown whether switching the bacillus Calmette-Guérin (BCG) strain at the second induction course of BCG therapy has a therapeutic benefit in patients with tumor recurrence after the initial BCG therapy (BCG-relapsing tumor).

Materials And Methods: We retrospectively reviewed the clinicopathological features of 97 patients treated with a second induction course of BCG therapy between 1986 and 2014. Among the patients initially treated with BCG Tokyo-172, the second course was either BCG Tokyo-172 in 56 (57. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.02.005DOI Listing
June 2018
1 Read

Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study.

Am J Clin Nutr 2018 Feb;107(2):208-216

Departments of Epidemiology and Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Background: Patients with cancer are highly concerned about food choices and dietary supplements that may affect their treatment outcomes. Excess folic acid (synthetic folate) from supplements or fortification can lead to accumulation of unmetabolized folic acid in the systemic circulation and urine and may promote cancer growth, especially among those with neoplastic alterations.

Objective: We investigated the prospective association between synthetic compared with natural folate intake and clinical outcomes in non-muscle-invasive bladder cancer (NMIBC), which is a highly recurrent disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcn/nqx019DOI Listing
February 2018
3 Reads

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.

BMC Cancer 2018 02 17;18(1):194. Epub 2018 Feb 17.

INSERM U1194, Montpellier Cancer Research Institute, Montpellier, France.

Background: Bladder cancer is the 7th cause of death from cancer in men and 10th in women. Metastatic patients have a poor prognosis with a median overall survival of 14 months. Until recently, vinflunine was the only second-line chemotherapy available for patients who relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4059-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816357PMC
February 2018
9 Reads

Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.

Oncology (Williston Park) 2017 12;31(12):855-62

Cystoscopy and urine cytology are the gold-standard tests for detection of recurrent disease during follow-up in patients with a history of non-muscle-invasive bladder cancer (NMIBC). High associated costs, as well as side effects, have driven the desire for inexpensive, noninvasive, accurate, and easy-to-use urine markers to detect bladder cancer recurrence. While many urine markers have been developed, very few have been clinically implemented. Read More

View Article

Download full-text PDF

Source
December 2017
7 Reads

Familial risks in urolithiasis in the population of Sweden.

BJU Int 2018 03 14;121(3):479-485. Epub 2018 Jan 14.

Center for Primary Health Care Research, Lund University, Malmö, Sweden.

Objective: To assess detailed familial risks for medically diagnosed urolithiasis (UL, urinary tract stone disease) based on nationwide hospital and population records.

Patients/subjects And Methods: Subjects were identified from the Swedish Multigeneration Register in which there were 211 718 patients with UL. Standardised incidence ratios (SIRs) were calculated by comparison to individuals without a family history of UL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14096DOI Listing
March 2018
10 Reads

Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.

J Urol 2018 May 2;199(5):1158-1165. Epub 2017 Dec 2.

Cleveland Clinic, Cleveland, Ohio.

Purpose: We compared blue light flexible cystoscopy with white light flexible cystoscopy for the detection of bladder cancer during surveillance.

Materials And Methods: Patients at high risk for recurrence received hexaminolevulinate intravesically before white light flexible cystoscopy and randomization to blue light flexible cystoscopy. All suspicious lesions were documented. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00225347177800
Publisher Site
http://dx.doi.org/10.1016/j.juro.2017.11.096DOI Listing
May 2018
15 Reads

Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study.

Urology 2018 Mar 28;113:71-78. Epub 2017 Nov 28.

Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Objective: To clarify the clinical utility of urinary DNA methylation for detection of intravesical recurrence of non-muscle invasive BCa (NMIBC), we performed a 2-center prospective study.

Patients And Methods: A series of 207 self-voided urine samples were prospectively collected from 132 patients with NMIBC who had undergone transurethral resection of BCa. Methylation of miRNA genes (miR-9-3, miR-124-2, miR-124-3, and miR-137) was analyzed using bisulfite pyrosequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2017.11.025DOI Listing
March 2018
7 Reads

DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.

BMC Cancer 2017 Nov 15;17(1):767. Epub 2017 Nov 15.

Division of Surgery and Interventional Science, University College London, 74 Huntley Street, London, WC1E 6AU, UK.

Background: Haematuria is a common finding in general practice which requires visual inspection of the bladder by cystoscopy as well as upper tract imaging. In addition, patients with non-muscle invasive bladder cancer (NMIBC) often require surveillance cystoscopy as often as three monthly depending on disease risk. However, cystoscopy is an invasive procedure which is uncomfortable, requires hospital attendance and is associated with a risk of urinary tract infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3758-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688623PMC
November 2017
16 Reads

Multidetector Computed Tomographic Urography (MDCTU): Its Practical Role in Diagnosis of Upper Tract Urothelial Cancer in Patients 50 years and Older with Different Types of Hematuria.

Pathol Oncol Res 2019 Jan 30;25(1):249-254. Epub 2017 Oct 30.

Epidemiology and Statistics, Ben Gurion University, Beersheba, Israel.

MDCTU is a preferred method for the investigation of malignant lesions in the upper urinary tract. However, to decrease unnecessary radiation exposure the indications for the exam in different groups of patients should be assessed. In this study, we evaluated the role of MDCTU in patients older than 50 years who presented with different types of hematuria. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12253-017-0333-0
Publisher Site
http://dx.doi.org/10.1007/s12253-017-0333-0DOI Listing
January 2019
19 Reads

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review.

Eur Urol 2018 05 18;73(5):738-748. Epub 2017 Oct 18.

Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.

Context: Bacillus Calmette-Guérin (BCG) is currently the most effective intravesical therapy for nonmuscle invasive bladder cancer, reducing not only recurrence rates but also preventing progression and reducing deaths. However, response rates to BCG vary widely and are dependent on a multitude of factors.

Objective: To review existing data on clinical, pathologic, immune, and molecular markers that allow prediction of BCG response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.10.003DOI Listing
May 2018
21 Reads

Occupations and the Risk of Bladder Cancer in Yazd Province: A Case-Control Study.

Int J Occup Environ Med 2017 10;8(4):191-198

Department of Epidemiology and Biostatistics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Background: Bladder cancer is the most common cancer of the urinary tract, with known occupational causes. The most effective way to prevent occupational cancers of the urinary tract is to prevent exposure to known carcinogens.

Objective: To examine the relationship between occupation and the risk of bladder cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15171/ijoem.2017.1085DOI Listing
October 2017
1 Read

Retrograde pyelography predicts retrograde ureteral stenting failure and reduces unnecessary stenting trials in patients with advanced non-urological malignant ureteral obstruction.

PLoS One 2017 20;12(9):e0184965. Epub 2017 Sep 20.

Department of Urology, Center for Prostate Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea.

Objective: To evaluate predictive factors for retrograde ureteral stent failure in patients with non-urological malignant ureteral obstruction.

Materials And Methods: Between 2005 and 2014, medical records of 284 malignant ureteral obstruction patients with 712 retrograde ureteral stent trials including 63 (22.2%) having bilateral malignant ureteral obstruction were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0184965PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607161PMC
October 2017
11 Reads

Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes.

World J Urol 2017 Dec 14;35(12):1879-1884. Epub 2017 Sep 14.

Department of Urology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.

Purpose: To evaluate perioperative and oncologic outcomes of patients undergoing radical cystectomy (RC) for recurrence of urothelial carcinoma (UC) after prior partial cystectomy (PC), and to compare these outcomes to patients undergoing primary RC.

Methods: Patients who underwent RC for recurrence of UC after prior PC were matched 1:3 to patients undergoing primary RC based on age, pathologic stage, and decade of surgery. Perioperative and oncologic outcomes were compared using Wilcoxon sign-rank test, McNemars test, the Kaplan-Meier method, and Cox proportional hazards regression analyses. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00345-017-2087-4
Publisher Site
http://dx.doi.org/10.1007/s00345-017-2087-4DOI Listing
December 2017
6 Reads

Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project.

J Urol 2018 Feb 26;199(2):401-406. Epub 2017 Aug 26.

Department of Urology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico-Clinical and Research Hospital, Milan, Italy; Business Operations Office, Humanitas Clinical and Research Center, Milan, Italy; Department of Biomedical Science, Humanitas University, Milan, Italy.

Purpose: We investigated predictive factors of failure and performed a resource consumption analysis in patients who underwent active surveillance for nonmuscle invasive bladder cancer.

Materials And Methods: This prospective observational study monitored patients with a history of pathologically confirmed stage pTa (grade 1-2) or pT1a (grade 2) nonmuscle invasive bladder cancer, and recurrent small size and number of tumors without hematuria and positive urine cytology. The primary end point was the failure rate of active surveillance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2017.08.091DOI Listing
February 2018
24 Reads

Surgical and pathological outcomes of robotic-assisted radical cystectomy for bladder cancer in the community setting.

J Robot Surg 2018 Jun 23;12(2):337-341. Epub 2017 Aug 23.

The University of Arizona College of Medicine - Phoenix, Phoenix, Arizona, USA.

Robotic-assisted radical cystectomy (RARC) with urinary diversion is commonly performed in community hospitals. While little data exist on RARC outcomes in this setting, community hospitals may improve access to care for bladder cancer patients. We conducted a retrospective review of 76 patients who underwent RARC between 2006 and 2016 by two robotic-trained surgeons in two local community hospitals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11701-017-0740-yDOI Listing
June 2018
25 Reads

[Sacral resection in surgical treatment of locally advanced primary and recurrent rectal and anal cancer: short-term outcomes].

Khirurgiia (Mosk) 2017(7):4-13

Sechenov First Moscow State Medical University, Department of colorectal and endoscopic surgery, Moscow, Russia.

Aim: To assess safety of rectum removal with distal sacral resection.

Material And Methods: The short-term results of surgical treatment of primary and recurrent locally advanced rectal and anal cancer with sacral fixation have been analyzed. 32 patients underwent combined operations with sacral resection at the level of S2-S5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/hirurgia201774-13DOI Listing
November 2017
3 Reads

The impact of incontinence etiology on artificial urinary sphincter outcomes.

Investig Clin Urol 2017 07 27;58(4):241-246. Epub 2017 Jun 27.

Department of Urology, Mayo Clinic, Rochester, MN, USA.

Purpose: To evaluate the impact of incontinence etiology on artificial urinary sphincter (AUS) device outcomes.

Materials And Methods: We identified 925 patients who underwent primary AUS placement from 1983 to 2011. The etiology of incontinence was categorized as radical prostatectomy alone, radical prostatectomy with radiation, benign prostate resection, and those with cryotherapy as a salvage prostate cancer treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4111/icu.2017.58.4.241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494347PMC
July 2017
1 Read

Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly.

Anticancer Res 2017 06;37(6):3287-3290

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany

Aim: The number of very elderly patients with cancer is growing and requires particular attention. The role of organ-sparing irradiation in patients with bladder cancer aged ≥80 years was investigated.

Patients And Methods: In 29 very elderly (≥80 years) patients irradiated for bladder cancer, 12 characteristics were analysed for survival: indication, gender, age, Karnofsky performance score (KPS), T-/N-category, tumour grade, pack years, smoking during irradiation, radiation dose, interruption of irradiation >5 days and concurrent chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.11694DOI Listing
June 2017
7 Reads

Prediction of Multiple Recurrent Events: A Comparison of Extended Cox Models in Bladder Cancer.

Am J Epidemiol 2017 Sep;186(5):612-623

Recurrence of bladder cancer can occur repeatedly in the same patient after treatment of the primary tumor. Models predicting the risk of a next recurrence may inform individualized decision-making on surveillance frequency. We aimed to assess the usefulness of extensions of the Cox proportional hazards model for repeated events in this context. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/aje/kwx133DOI Listing
September 2017
21 Reads

Immune Checkpoint Blockade in Metastatic Urothelial Cancer.

J Clin Oncol 2017 Jul 8;35(19):2109-2112. Epub 2017 May 8.

Arjun Vasant Balar, New York University, New York, NY.

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.8444DOI Listing
July 2017
22 Reads

Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer.

Cancer Causes Control 2017 Jul 5;28(7):755-766. Epub 2017 May 5.

Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Purpose: Radical cystectomy is a surgical treatment for recurrent non-muscle-invasive and muscle-invasive bladder cancer; however, many patients may not receive this treatment.

Methods: A total of 27,578 patients diagnosed with clinical stage I-IV bladder cancer from 1 January 2007 to 31 December 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) registry database. We used multivariable regression analyses to identify factors predicting the use of radical cystectomy and pelvic lymph node dissection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-017-0902-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497706PMC
July 2017
9 Reads

Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patients.

Sci Rep 2017 05 3;7(1):1380. Epub 2017 May 3.

Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea.

To evaluate the influence of patient-associated parameters and comorbities, with a special focus on renal function after intravesical adjuvant bacillus Calmette-Gue´rin (BCG) immunotherapy in patients with non-muscle-invasive bladder cancer (NMIBC). We retrospectively reviewed the medical records of patients treated from October, 1991 to December, 2013 at Seoul National University who were diagnosed with NMIBC and treated with intravesical BCG. A total of 344 patients who were diagnosed with NMIBC and treated with intravesical BCG were enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-01532-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431111PMC
May 2017
12 Reads

Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database.

BJU Int 2017 09 17;120(3):377-386. Epub 2017 May 17.

James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Objective: To investigate the length of time from initial haematuria presentation to upper tract urothelial carcinoma (UTUC) diagnosis and the effect of gender on this duration.

Patients And Methods: Patients with haematuria claims in the year prior to UTUC diagnosis were identified from the MarketScan database (2010-2014). Delayed diagnosis was defined as >90 days from haematuria presentation to UTUC diagnosis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bju.13878
Publisher Site
http://dx.doi.org/10.1111/bju.13878DOI Listing
September 2017
14 Reads

Epidemiology and pathophysiology of malignancy in common variable immunodeficiency?

Allergol Immunopathol (Madr) 2017 Nov - Dec;45(6):602-615. Epub 2017 Apr 12.

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Common variable immunodeficiency (CVID) is a diagnostic category of primary immunodeficiency (PID) which may present with heterogeneous disorders including recurrent infections, autoimmunity, granulomatous diseases, lymphoid and other types of malignancies. Generally, the incidence of malignancy in CVID patients is around 1.5-20. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aller.2017.01.006DOI Listing
June 2018
18 Reads

Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer.

Tumour Biol 2017 Apr;39(4):1010428317697552

1 National Institute of Pathology (Indian Council of Medical Research), New Delhi, India.

Urothelial cancer patients are prone to recurrence, and there is no marker to predict which cases become refractory to the immunotherapy given to these patients. Tumour behaviour is decided by the dynamics between the pro- and anti-tumorigenic cytokines. In this study, 27 cytokines were estimated in serum and urine of 72 urothelial cancer patients and 42 healthy volunteer controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1010428317697552DOI Listing
April 2017
5 Reads

Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.

Urol Oncol 2017 08 31;35(8):531.e15-531.e22. Epub 2017 Mar 31.

Pacific Edge Ltd., Dunedin, New Zealand.

Objective: Patients with urothelial carcinoma (UC) undergo rigorous surveillance for recurrence. Noninvasive urine tests are not currently recommended by guideline panels owing to insufficient clinical benefit. The objective of this study was to prospectively compare the performance of the Cxbladder Monitor test to other commonly available urine markers and cytology for surveillance of patients with UC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.03.008DOI Listing
August 2017
6 Reads

Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival-A Case Series.

Int J Gynecol Cancer 2017 05;27(4):759-767

*Department of Gynecology-Obstetrics and Urology, Sapienza University of Rome, Rome, Italy; †West London Gynaecological Cancer Centre, Imperial College Healthcare NHS Trust; ‡Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, United Kingdom; §Division of Obstetrics and Gynecology, Department of Biomedical, Clinical and Experimental Sciences, University of Florence, Florence, Italy; ∥Mount Vernon Cancer Centre, London, United Kingdom; ¶Department of Anaesthetics, Hammersmith Hospital, Imperial College Healthcare NHS Trust; and #Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.

Objective: The purpose of this study was to describe the patterns of relapse in uterine cancer (UC) and the role of surgery in the recurrent setting.

Methods: We describe surgical and clinical outcomes of all patients who underwent surgery for recurrent UC in a gynecological oncology tertiary referral center between May 1, 2013, and April 30, 2016. Progression-free survival and overall survival were estimated using Kaplan-Meier methods with the surgery at relapse being the starting point. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000936DOI Listing
May 2017
8 Reads

Neutrophil-to-lymphocyte ratio is elevated in recurringnonmuscle invasive bladder cancer.

Turk J Med Sci 2017 Feb 27;47(1):234-239. Epub 2017 Feb 27.

Department of Urology, Bağcılar Training & Research Hospital, İstanbul, Turkey.

Background/aim: Although it has been shown that the neutrophil-to-lymphocyte ratio (NLR) may predict the progression of nonmuscle invasive bladder cancer (NMIBC), its association with the recurrence of NMIBC has been poorly studied. The aim of this study is to evaluate the association between NLR and disease recurrence in patients with NMIBC.

Materials And Methods: The medical records of 428 consecutive initially diagnosed NMIBC patients who underwent transurethral resection between January 2010 and July 2014 were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3906/sag-1509-73DOI Listing
February 2017
13 Reads

Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer.

Eur Urol 2017 07 20;72(1):152. Epub 2017 Feb 20.

Department of Urology, Pitié-Salpêtrière Academic Hospital, Pierre and Marie Curie Medical School, University Paris 6, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838173010
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2017.02.017DOI Listing
July 2017
4 Reads

Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder.

Urol Oncol 2017 07 16;35(7):457.e15-457.e21. Epub 2017 Jan 16.

Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Purpose: We aimed to identify prognostic clinicopathological factors and to create a nomogram able to predict overall survival (OS) in recurrent urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC).

Materials And Methods: Among 1,087 patients with UCB who had undergone RC at our 11 institutions between 1990 and 2010, 306 patients who subsequently developed distant metastasis or local recurrence or both were identified. Clinical data were collected with medical record review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.12.010DOI Listing
July 2017
11 Reads

Update on the Diagnosis and Treatment of Cholangiocarcinoma.

Curr Gastroenterol Rep 2017 Jan;19(1)

Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Purpose Of Review: Cholangiocarcinoma is a rare biliary adenocarcinoma associated with poor outcomes. Cholangiocarcinoma is subdivided into extrahepatic and intrahepatic variants. Intrahepatic cholangiocarcinoma is then further differentiated into (1) peripheral mass-forming tumors and (2) central periductal infiltrating tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11894-017-0542-4DOI Listing
January 2017
11 Reads